RZLT Rezolute, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
20:04
Jan 27
Jan 27
RZLT undervalued after panic sell; upLIFT catalyst and OLE efficacy
The author argues RZLT is massively undervalued after a ~90% panic sell, because sunRIZE's failed endpoints were caused by a large placebo effect while the drug hit target drug levels and biomarkers moved as expected. The causal mechanism is that the open-label extension, with all 59 patients continuing and some on drug for 18 months, plus EAP tumour HI data showing 75% stopped IV glucose/TPN, signal real efficacy and support the single-arm Phase 3 upLIFT study. The stated bear risk is the primary and key secondary endpoint miss, which the author attributes to trial design rather than drug failure. The author frames this as a 2-5x growth opportunity, with upLIFT as the key ongoing catalyst.
HIGH
About RZLT Investor Commentary
Across the available history and selected sources, Buzzberg tracks RZLT (Rezolute, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Fuzzy-Eye-7976.